Pestend Pest Control Wins 2025 Consumer Choice Award for Pest Control in Toronto Central
TORONTO, ON / ACCESS Newswire / May 16, 2025 / Consumer Choice Award (CCA) is proud to announce that Pestend Pest Control has been named the 2025 Consumer Choice Award Winner in the Pest Control category for Toronto Central. This award highlights the company's outstanding reputation, professional expertise, and unwavering commitment to safe, effective pest and wildlife removal services throughout the region.
Serving the Greater Toronto Area, London, and Ottawa, Pestend Pest Control is a fully licensed pest and wildlife control company offering residential, commercial, and industrial services. Specializing in the treatment and removal of mice, rats, cockroaches, bed bugs, ants, wasps, crawling insects, and nuisance wildlife, the company has earned its place among Ontario's most trusted names in pest control.
'We're incredibly proud to be recognized with the Consumer Choice Award,' said the team at Pestend. 'This recognition reflects the effort we put into every job, the pride we take in our service, and the trust we've earned from customers who rely on us every day.'
With over 2,000 5-star Google reviews, Pestend Pest Control is one of the top-rated pest control companies in Ontario. From state-of-the-art extermination methods to eco-conscious solutions and long-term prevention strategies, the company remains focused on delivering quality with integrity.
Pestend Pest Control provides:
The company attributes its continued success to a simple formula: putting customers and employees first. This people-centred approach has allowed Pestend to grow through word-of-mouth, strong online reviews, and a loyal customer base.
The Consumer Choice Award is based on independent research and community feedback, ensuring that only the most outstanding service providers earn this prestigious recognition. Pestend's selection reflects its consistent delivery of trusted, high-quality services across one of Canada's most competitive markets.
To learn more about Pestend Pest Control or to request a quote, CLICK HERE or visit www.pestend.ca.
About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.
Contact Information:
Sumi Saleh
Communications Manager
[email protected]
SOURCE: Consumer Choice Award
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
MustGrow Biologics Corp (MGROF) Q1 2025 Earnings Call Highlights: A Promising Start with ...
Sales Revenue: $3.8 million for Q1 2025. Gross Profit: Approximately $540,000. Gross Margin: 14.3%. Cash Position: $2 million. NexusBioAg Sales: Historical sales between $15 million to $20 million, with expectations to maintain this range. Shares Outstanding: 52 million shares, 59 million fully diluted. Warning! GuruFocus has detected 5 Warning Signs with MGROF. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MustGrow Biologics Corp (MGROF) reported $3.8 million in sales revenue for Q1 2025, marking a significant milestone as their initial sales numbers. The company successfully integrated NexusBioAg, a sales and distribution division, which contributed to the Q1 sales. MustGrow Biologics Corp (MGROF) has a strong partnership with Bayer, which includes a commercial agreement in Europe, Middle East, and Africa, with potential for milestone and royalty payments. The company holds 112 patents, showcasing a robust intellectual property portfolio, and is actively working on new IP generation. MustGrow Biologics Corp (MGROF) is focusing on a high-growth, asset-light model, with a tight capital structure and plans to drive revenue and margin growth. The gross margin for Q1 2025 was 14.3%, which was negatively affected by foreign exchange fluctuations and tariffs. Sales for TerraSante have not yet ramped up significantly, with expectations for more meaningful sales in late 2025 or early 2026. The company faces challenges with the registration process for TerraMG, with potential registration not expected until 2026. MustGrow Biologics Corp (MGROF) is assessing the need for additional working capital to drive revenue growth, indicating potential financial constraints. The agricultural market's seasonality and cyclicality present challenges in sales predictability and revenue generation. Q: Sales so far were all from Canada, right? Were any of them from TerraSante? A: Yes, Q1 sales were all in Canada, specifically through NexusBioAg. TerraSante sales in the US are expected to ramp up in the second half of this year. Q: How have tariffs affected sales, specifically for TerraSante? A: Our products were not directly affected by tariffs, but there were indirect effects such as a weaker Canadian dollar, which negatively impacted margins. Q: Are you able to provide any sort of a forecast for TerraSante? A: No, we do not provide forecasts at this time. Q: Is the regenerative or natural input market for agriculture growing faster than traditional inputs? A: Yes, the regenerative agriculture market is growing at a significant double-digit CAGR compared to the single-digit growth of the synthetic market. Q: When do you expect to see positive free cash flow? A: Our goal is to achieve positive cash flows next year, potentially into 2027, by driving revenues and margins. Q: Do you need more working capital for inventory to drive your revenues? A: Yes, we are assessing access to capital, including non-dilutive options, to support revenue and margin growth. Q: Are there any updates on the registration process for TerraMG? A: In North America, we are progressing with registrations and hope to have them by 2026. Bayer is also working on registrations in Europe, the Middle East, and Africa. Q: Does NexusBioAg only focus on Western Canada, or do they have a presence in Eastern Canada as well? A: NexusBioAg has coverage across Canada, with significant operations in both Western and Eastern Canada. Q: Are there any more impactful products in the pipeline to run through Nexus? A: Yes, there are many products in the pipeline, and we are leveraging Nexus's market access and relationships to introduce them. Q: Is there a push to open up or get approval in more US states? A: Currently, we are focusing on accelerating sales in California, Washington, Oregon, and Idaho, with potential expansion to other states being assessed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
4 hours ago
- Yahoo
MustGrow Biologics Corp (MGROF) Q1 2025 Earnings Call Highlights: A Promising Start with ...
Sales Revenue: $3.8 million for Q1 2025. Gross Profit: Approximately $540,000. Gross Margin: 14.3%. Cash Position: $2 million. NexusBioAg Sales: Historical sales between $15 million to $20 million, with expectations to maintain this range. Shares Outstanding: 52 million shares, 59 million fully diluted. Warning! GuruFocus has detected 5 Warning Signs with MGROF. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MustGrow Biologics Corp (MGROF) reported $3.8 million in sales revenue for Q1 2025, marking a significant milestone as their initial sales numbers. The company successfully integrated NexusBioAg, a sales and distribution division, which contributed to the Q1 sales. MustGrow Biologics Corp (MGROF) has a strong partnership with Bayer, which includes a commercial agreement in Europe, Middle East, and Africa, with potential for milestone and royalty payments. The company holds 112 patents, showcasing a robust intellectual property portfolio, and is actively working on new IP generation. MustGrow Biologics Corp (MGROF) is focusing on a high-growth, asset-light model, with a tight capital structure and plans to drive revenue and margin growth. The gross margin for Q1 2025 was 14.3%, which was negatively affected by foreign exchange fluctuations and tariffs. Sales for TerraSante have not yet ramped up significantly, with expectations for more meaningful sales in late 2025 or early 2026. The company faces challenges with the registration process for TerraMG, with potential registration not expected until 2026. MustGrow Biologics Corp (MGROF) is assessing the need for additional working capital to drive revenue growth, indicating potential financial constraints. The agricultural market's seasonality and cyclicality present challenges in sales predictability and revenue generation. Q: Sales so far were all from Canada, right? Were any of them from TerraSante? A: Yes, Q1 sales were all in Canada, specifically through NexusBioAg. TerraSante sales in the US are expected to ramp up in the second half of this year. Q: How have tariffs affected sales, specifically for TerraSante? A: Our products were not directly affected by tariffs, but there were indirect effects such as a weaker Canadian dollar, which negatively impacted margins. Q: Are you able to provide any sort of a forecast for TerraSante? A: No, we do not provide forecasts at this time. Q: Is the regenerative or natural input market for agriculture growing faster than traditional inputs? A: Yes, the regenerative agriculture market is growing at a significant double-digit CAGR compared to the single-digit growth of the synthetic market. Q: When do you expect to see positive free cash flow? A: Our goal is to achieve positive cash flows next year, potentially into 2027, by driving revenues and margins. Q: Do you need more working capital for inventory to drive your revenues? A: Yes, we are assessing access to capital, including non-dilutive options, to support revenue and margin growth. Q: Are there any updates on the registration process for TerraMG? A: In North America, we are progressing with registrations and hope to have them by 2026. Bayer is also working on registrations in Europe, the Middle East, and Africa. Q: Does NexusBioAg only focus on Western Canada, or do they have a presence in Eastern Canada as well? A: NexusBioAg has coverage across Canada, with significant operations in both Western and Eastern Canada. Q: Are there any more impactful products in the pipeline to run through Nexus? A: Yes, there are many products in the pipeline, and we are leveraging Nexus's market access and relationships to introduce them. Q: Is there a push to open up or get approval in more US states? A: Currently, we are focusing on accelerating sales in California, Washington, Oregon, and Idaho, with potential expansion to other states being assessed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Saputo Inc (SAPIF) Q4 2025 Earnings Call Highlights: Strong Domestic Growth Amid International ...
Revenue: $4.8 billion in the fourth quarter, a 5% increase year-over-year. Adjusted EBITDA: $365 million for the fourth quarter. Net Earnings: $74 million for the fourth quarter; adjusted net earnings of $128 million, down $28 million year-over-year. Canada Sector Revenue: Nearly $1.3 billion, a 6% increase year-over-year. Canada Sector Adjusted EBITDA: $157 million, up 14% year-over-year. USA Sector Revenue: $2.1 billion, an 11% increase year-over-year. USA Sector Adjusted EBITDA: $148 million, a 7% increase year-over-year. International Sector Revenue: $1 billion, down 10% year-over-year. International Sector Adjusted EBITDA: $47 million, down $41 million year-over-year. Europe Sector Revenue: $335 million. Europe Sector Adjusted EBITDA: $24 million. Net Cash from Operating Activities: $362 million for the fourth quarter. Capital Expenditures (CapEx): $113 million for the fourth quarter. Net Debt to Adjusted EBITDA Ratio: 2.1x as of March 31, 2025. Share Repurchases: Approximately $150 million in shares repurchased under the NCIB program in fiscal year 2025. Warning! GuruFocus has detected 4 Warning Signs with SAPIF. Release Date: June 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Saputo Inc (SAPIF) reported a 5% increase in consolidated revenues, reaching $4.8 billion, driven by higher domestic selling prices and international market prices. The company achieved $150 million in share repurchases under its NCIB program, reflecting strong financial health and commitment to shareholder value. Operational efficiencies and strategic initiatives led to a 14% increase in adjusted EBITDA in the Canadian sector. The USA sector saw an 11% revenue increase and achieved $27 million in cost savings, contributing to an 18% year-over-year growth in adjusted EBITDA. Saputo Inc (SAPIF) is advancing its digital technology adoption to enhance operational efficiency and customer value, positioning itself for future growth. The international sector faced challenges due to currency devaluation and hyperinflation in Argentina, impacting overall performance. Net earnings for the fourth quarter were down $28 million compared to the previous year, primarily due to higher depreciation and financial charges. The European sector continues to face challenges with inflationary pressures and lower margins, despite some recovery in sales volume. Softening consumer demand, particularly in the food service channel, was observed, affecting volumes in the USA sector. The Argentina division experienced higher production costs and reduced milk availability, contributing to a decline in adjusted EBITDA. Q: Carl, the outlook section seems more confident than in previous years. Can you comment on where you're feeling most confident and where you see potential challenges? A: Carl Colizza, President and CEO: The business is performing well, and we've made significant investments over the past few years. We feel strongly about our capabilities and the diversity of our portfolio. North America, particularly the US, presents the greatest upside due to our capital investments. We expect growth across all sectors. Q: Can you expand on the acceleration of investment in priority regions? A: Carl Colizza, President and CEO: We've been exploring new markets, especially in Southeast Asia, Japan, and the Middle East, due to trade dynamics and dairy demand shifts. This expansion helps us maintain our baseline and establish ourselves as a credible supplier in new areas, which is a multiyear process. Q: How are you addressing SG&A optimization, and what impact will it have in fiscal '26? A: Carl Colizza, President and CEO: We've reshaped business processes and adopted digital technologies to focus resources on high-value areas. This led to a reduction in workforce, resulting in structural changes that will benefit cost efficiency and operational effectiveness. Q: Can you discuss the situation in Argentina and the potential impact of currency control relaxation and slowing inflation? A: Carl Colizza, President and CEO: Milk supply is improving, and currency stability is aiding pricing strategies. Maxime Therrien, CFO, added that Argentina's agreement with the IMF is expected to stabilize the economy, reducing inflation and currency volatility, which should positively impact our financial results. Q: How do you plan to manage the increased milk prices in Australia, and can you pass these costs on domestically? A: Carl Colizza, President and CEO: Our competitive opening price aligns with consumer willingness to pay and international demand. We continue to support our farming community and recover costs through balanced pricing strategies, ensuring it doesn't detrimentally impact our bottom line. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
